Abstract

Background: Acute Myeloid Leukemia (AML) is a complex and heterogeneous hematologic malignancy. However, the function of prognosis-related signature genes in AML remains unclear. Methods: In the current study, transcriptome sequencing was performed on 15 clinical samples, differentially expressed RNAs were identified using R software. The potential interactions network was constructed by using the common genes between target genes of differentially expressed miRNAs with transcriptome sequencing results. Functional and pathway enrichment analysis was performed to identify candidate gene-mediated aberrant signaling pathways. Hub genes were identified by the cytohubba plugin in Cytoscape software, which then expanded the potential interactions regulatory module for hub genes. TCGA-LAML clinical data were used for the prognostic analysis of the hub genes in the regulatory network, and GVSA analysis was used to identify the immune signature of prognosis-related hub genes. qRT-PCR was used to verify the expression of hub genes in independent clinical samples. Results: We obtained 1,610 differentially expressed lncRNAs, 233 differentially expressed miRNAs, and 2,217 differentially expressed mRNAs from transcriptome sequencing. The potential interactions network is constructed by 12 lncRNAs, 25 miRNAs, and 692 mRNAs. Subsequently, a sub-network including 15 miRNAs as well as 12 lncRNAs was created based on the expanded regulatory modules of 25 key genes. The prognostic analysis results show that CCL5 and lncRNA UCA1 was a significant impact on the prognosis of AML. Besides, we found three potential interactions networks such as lncRNA UCA1/hsa-miR-16-5p/COL4A5, lncRNA UCA1/hsa-miR-16-5p/SPARC, and lncRNA SNORA27/hsa-miR-17-5p/CCL5 may play an important role in AML. Furthermore, the evaluation of the immune infiltration shows that CCL5 is positively correlated with various immune signatures, and lncRNA UCA1 is negatively correlated with the immune signatures. Finally, the result of qRT-PCR showed that CCL5 is down-regulated and lncRNA UCA1 is up-regulated in AML samples separately. Conclusions: In conclusion, we propose that CCL5 and lncRNA UCA1 could be recognized biomarkers for predicting survival prognosis based on constructing competing endogenous RNAs in AML, which will provide us novel insight into developing novel prognostic, diagnostic, and therapeutic for AML.

Highlights

  • Acute Myeloid Leukemia (AML) is one of the most common hematologic malignancies in adults and is characterized by a clonal expansion of myeloid abnormally differentiated blast cells (Short et al, 2018)

  • To identify differentially expressed messenger RNA (mRNA), long non-coding RNAs (lncRNAs), and miRNAs between 10 AML and five control patients differentially, total Bone Marrow Mononuclear Cells (BMNCs) were collected for whole transcriptome sequencing

  • The Urothelial carcinoma-associated 1 (UCA1) expression levels were related to TAM, CAFs, CD8 cells, MDSC, and M2 macrophages (Spearman’s correlation test, p

Read more

Summary

Introduction

Acute Myeloid Leukemia (AML) is one of the most common hematologic malignancies in adults and is characterized by a clonal expansion of myeloid abnormally differentiated blast cells (Short et al, 2018). It should be noted that the data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program report that the overall incidence trend for AML appears to be slowly increasing (Henley et al, 2020) and that this may be inextricably linked to differences in genetic and biological characteristics and an aging population (Rodriguez-Abreu et al, 2007; Lancet, 2018). Despite significant advances in the genetic landscape of AML, standard treatments have not improved significantly over the past 30 years (Tyner et al, 2018). Acute Myeloid Leukemia (AML) is a complex and heterogeneous hematologic malignancy. The function of prognosis-related signature genes in AML remains unclear

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call